$5.22
8.62% day before yesterday
Nasdaq, Dec 27, 09:46 pm CET
ISIN
US0396971071
Symbol
ARDX
Sector
Industry

Ardelyx, Inc. Stock price

$5.21
-0.48 8.44% 1M
-1.29 19.85% 6M
-0.99 15.97% YTD
-1.31 20.09% 1Y
+4.13 382.41% 3Y
-2.24 30.07% 5Y
-15.02 74.25% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.40 8.32%
ISIN
US0396971071
Symbol
ARDX
Sector
Industry

Key metrics

Market capitalization $1.23b
Enterprise Value $1.15b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.56
P/S ratio (TTM) P/S ratio 4.90
P/B ratio (TTM) P/B ratio 7.80
Revenue growth (TTM) Revenue growth 87.57%
Revenue (TTM) Revenue $251.85m
EBIT (operating result TTM) EBIT $-64.06m
Free Cash Flow (TTM) Free Cash Flow $-63.80m
Cash position $190.40m
EPS (TTM) EPS $-0.31
P/E forward negative
P/S forward 3.78
EV/Sales forward 3.52
Short interest 11.67%
Show more

Is Ardelyx, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Ardelyx, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Ardelyx, Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Ardelyx, Inc. forecast:

Buy
80%
Hold
20%

Financial data from Ardelyx, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
252 252
88% 88%
100%
- Direct Costs 39 39
101% 101%
16%
213 213
85% 85%
84%
- Selling and Administrative Expenses 228 228
131% 131%
91%
- Research and Development Expense 46 46
36% 36%
18%
-62 -62
235% 235%
-25%
- Depreciation and Amortization 1.91 1.91
59% 59%
1%
EBIT (Operating Income) EBIT -64 -64
177% 177%
-25%
Net Profit -73 -73
173% 173%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Ardelyx, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ardelyx, Inc. Stock News

Negative
Seeking Alpha
about one month ago
Ardelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantly reduces its revenue, forcing Ardelyx to negotiate complex reimbursements. The Kidney PATIENT Act, if passed, will delay the inclusion of oral-only ESRD drugs in the bundled payment system, benefi...
Neutral
GlobeNewsWire
about one month ago
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside...
Negative
Seeking Alpha
about one month ago
Ardelyx's Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS's recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah's reimbursement prospects, creating significant regulatory uncertainty and limiting Ardelyx's revenue control. Ibsrela faces substantial competition in the IBS-C market, with lofty revenue projections likely overstati...
More Ardelyx, Inc. News

Company Profile

Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Head office United States
CEO Mike Raab
Employees 267
Founded 2007
Website www.ardelyx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today